MedTrace Logo

Secukinumab Efficacy Without the Initial Loading Dose in Patients With Psoriasis

NCT03828643 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 156

Last updated 2019-04-16

No results posted yet for this study

Summary

This was a retrospective, observational study. The objective of the study is investigate the efficacy and safety of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis. Patients were stratified in two groups, those receiving secukinumab at the dose 300 mg every 4 weeks from the beginning (cases) and those who received the initial label, weekly loading dose (controls). Efficacy was evaluated by comparing the proportion of patients achieving PASI75 responses at week 16, 32 and 48 between cases and controls. Safety was evaluated by reporting every adverse events up to week 48.

Conditions

  • Psoriasis Vulgaris

Interventions

DRUG

Secukinumab

Secukinumab 300 mg without loading dose at weeks 0, 1, 2, 3 and 4.

DRUG

Secukinumab

Secukinumab 300 mg with loading dose at weeks 0, 1, 2, 3 and 4.

Sponsors & Collaborators

  • Universita di Verona

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-20
Primary Completion
2019-04-12
Completion
2019-04-12
FDA Drug
Yes

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03828643 on ClinicalTrials.gov